癌症中的衰老

IF 48.8 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2025-06-12 DOI:10.1016/j.ccell.2025.05.015

Manuel Colucci, Miles Sarill, Martino Maddalena, Aurora Valdata, Martina Troiani, Martina Massarotti, Marco Bolis, Silvia Bressan, Anna Kohl, Daniele Robesti, Miriam Saponaro, Qiu Shi, Pan Song, Daniela Brina, Bianca Calì, Andrea Alimonti

{"title":"癌症中的衰老","authors":"Manuel Colucci, Miles Sarill, Martino Maddalena, Aurora Valdata, Martina Troiani, Martina Massarotti, Marco Bolis, Silvia Bressan, Anna Kohl, Daniele Robesti, Miriam Saponaro, Qiu Shi, Pan Song, Daniela Brina, Bianca Calì, Andrea Alimonti","doi":"10.1016/j.ccell.2025.05.015","DOIUrl":null,"url":null,"abstract":"Cellular senescence is a state of stable cell-cycle arrest induced by various intrinsic and extrinsic stressors, serving as a protective mechanism to prevent the proliferation of damaged cells. While this process is crucial for tissue homeostasis and tumor suppression, the progressive accumulation of senescent cells (SnCs) over time is implicated in age-related pathologies, including immune dysfunction and cancer. In oncology, senescence plays a paradoxical role: it can inhibit tumor development by halting the growth of potentially malignant cells, yet it may also facilitate tumor progression through the senescence-associated secretory phenotype (SASP). This review explores the defining features of senescence in cancer, its complex interactions with tumor cells, the stroma, and the immune system, and its context-dependent outcomes. We also discuss current and emerging therapeutic strategies that target SnCs—either by inducing or eliminating them—as well as AI-driven approaches for their detection and characterization in cancer.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":"6 1","pages":""},"PeriodicalIF":48.8000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Senescence in cancer\",\"authors\":\"Manuel Colucci, Miles Sarill, Martino Maddalena, Aurora Valdata, Martina Troiani, Martina Massarotti, Marco Bolis, Silvia Bressan, Anna Kohl, Daniele Robesti, Miriam Saponaro, Qiu Shi, Pan Song, Daniela Brina, Bianca Calì, Andrea Alimonti\",\"doi\":\"10.1016/j.ccell.2025.05.015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cellular senescence is a state of stable cell-cycle arrest induced by various intrinsic and extrinsic stressors, serving as a protective mechanism to prevent the proliferation of damaged cells. While this process is crucial for tissue homeostasis and tumor suppression, the progressive accumulation of senescent cells (SnCs) over time is implicated in age-related pathologies, including immune dysfunction and cancer. In oncology, senescence plays a paradoxical role: it can inhibit tumor development by halting the growth of potentially malignant cells, yet it may also facilitate tumor progression through the senescence-associated secretory phenotype (SASP). This review explores the defining features of senescence in cancer, its complex interactions with tumor cells, the stroma, and the immune system, and its context-dependent outcomes. We also discuss current and emerging therapeutic strategies that target SnCs—either by inducing or eliminating them—as well as AI-driven approaches for their detection and characterization in cancer.\",\"PeriodicalId\":9670,\"journal\":{\"name\":\"Cancer Cell\",\"volume\":\"6 1\",\"pages\":\"\"},\"PeriodicalIF\":48.8000,\"publicationDate\":\"2025-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Cell\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ccell.2025.05.015\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ccell.2025.05.015","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

细胞衰老是由各种内源性和外源性应激源诱导的细胞周期稳定停滞状态，是一种防止受损细胞增殖的保护机制。虽然这一过程对组织稳态和肿瘤抑制至关重要，但随着时间的推移，衰老细胞（SnCs）的渐进式积累与年龄相关的病理有关，包括免疫功能障碍和癌症。在肿瘤学中，衰老扮演着一个矛盾的角色：它可以通过阻止潜在恶性细胞的生长来抑制肿瘤的发展，但它也可能通过衰老相关的分泌表型（SASP）促进肿瘤的进展。这篇综述探讨了癌症中衰老的定义特征，它与肿瘤细胞、基质和免疫系统的复杂相互作用，以及它的环境依赖性结果。我们还讨论了当前和新兴的针对sncs的治疗策略-通过诱导或消除sncs -以及人工智能驱动的方法在癌症中检测和表征sncs。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Senescence in cancer

Cellular senescence is a state of stable cell-cycle arrest induced by various intrinsic and extrinsic stressors, serving as a protective mechanism to prevent the proliferation of damaged cells. While this process is crucial for tissue homeostasis and tumor suppression, the progressive accumulation of senescent cells (SnCs) over time is implicated in age-related pathologies, including immune dysfunction and cancer. In oncology, senescence plays a paradoxical role: it can inhibit tumor development by halting the growth of potentially malignant cells, yet it may also facilitate tumor progression through the senescence-associated secretory phenotype (SASP). This review explores the defining features of senescence in cancer, its complex interactions with tumor cells, the stroma, and the immune system, and its context-dependent outcomes. We also discuss current and emerging therapeutic strategies that target SnCs—either by inducing or eliminating them—as well as AI-driven approaches for their detection and characterization in cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.